Skip to main content
. Author manuscript; available in PMC: 2014 Mar 3.
Published in final edited form as: Crit Rev Oncol Hematol. 2012 Jun 16;85(1):82–93. doi: 10.1016/j.critrevonc.2012.05.003

Table 2.

Potential predictors of survival (biomarkers of outcome)

Performance status
Co-morbidities [96]
Gleason grading score
Prostate specific antigen (PSA half-time, PSA nadir, time to PSA nadir, PSA doubling time after PSA nadir)
Inflammatory markers (C-reactive protein, IL-6)
Metabolic markers (body mass index, bone turnover markers)
Circulating tumor cells (CTC) / CTC genomic characteristics